The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Zanubrutinib monotherapy in R/R indolent NHL
Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, describes the safety and efficacy results from a Phase I/II, open-label, multicenter, single-agent study of the Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma. The results of this study suggest a favorable benefit-risk profile and support zanubrutinib as a potentially meaningful addition to available therapies for patients with R/R marginal zone lymphoma (MZL) and follicular lymphoma (FL). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
